MME and diabetes mellitus: Activity of NEP enzyme, the primary target of Sacubitril, was quantified in plasma of a sub-cohort of pre-HFpEF patients with DM from the PARABLE trial [15] (n = 60/250) to understand impact of Sacubitril/Valsartan in this specific population.